To reduce the presence of multimers, 2% glycine was added to the emulsion as described [21]. Fig. 6 demonstrates a representative SDS-PAGE gel of protein extracted from an emulsion containing glycine TSA HDAC order showing no multimer formation; indicating that glycine could protect emulsions from multimer formation. Since PfCP-2.9 immunogenicity is

contingent on its conformation, it was necessary to investigate the conformational integrity of emulsified PfCP-2.9. Therefore, we developed a sandwich ELISA to quantitatively evaluate the presence of denatured versus intact protein in vaccine formulations stored at 4 °C over various periods. This was carried out by establishing a standard curve derived from testing different mixtures of denatured and intact PfCP-2.9. As shown in Fig. 7, the OD450 reading of the mixed emulsion preparations decreased

gradually from the highest value, 1.766 (100% intact protein emulsion) to the lowest value, 0.058867 (100% denatured protein emulsion). Each mixed emulsion sample was tested ten times independently to calculate the mean values and to establish the 95% confidence interval. Using this standard curve to assess protein integrity, we tested the OD450 values of vaccine emulsion preparations stored MS-275 concentration at 4 °C for 6, 12 and 18 months. The results showed that the mean value of these samples were 1.6515, 1.6660 and 1.7454, respectively, which were within the range of the 95% confidence interval of the 100% intact protein emulsion sample (positive control), indicating that the conformation of the protein in the emulsion stored for 18 months remained unchanged. The immunologic potency of the stored vaccine formulations was tested by comparing immunity induced by the stored samples to that elicited by fresh formulations. The

reference ED50 that obtained from three batches of standard fresh samples was 0.079, 0.031, and 0.060 μg, respectively. The ED50 of the samples stored for 6 and 12 months at 4 °C were 0.046 and 0.040 μg, respectively, which showed no significant changes in immunogenicity compared with the reference control (Table 1). The immunogenicity of the fresh and stored vaccine emulsions were evaluated in rabbits. After the fourth immunization, the immune sera obtained after the fourth immunization Rolziracetam was measured for specific anti-PfCP-2.9 antibodies by ELISA. These results indicated that the antibody titers in rabbits immunized with the stored emulsions at 4 °C for 3, 6, 9 and 12 months were 1.93 × 106, 1.91 × 106, 2.02 × 106, and 1.94 × 106, respectively, showing no significant differences compared with the fresh emulsion (P > 0.05). The specific antibodies induced by the vaccine emulsion stored at 4 °C for various periods were also evaluated for their ability to inhibit parasite growth in vitro. As shown in Fig. 8, the immune sera at 15% final concentration from rabbits immunized with the vaccine formulation stored for 0, 3, 6, 9 and 12 months effectively inhibited parasite growth at a similar level.